Cargando…

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations

Detalles Bibliográficos
Autores principales:	Hayat, Mahtaab, Kerr, Robyn, Bentley, Amy R., Rotimi, Charles N., Raal, Frederick J., Ramsay, Michèle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996995/ https://www.ncbi.nlm.nih.gov/pubmed/33770136 http://dx.doi.org/10.1371/journal.pone.0249478

Ejemplares similares

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2020)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

Variable expressivity and co‐occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy
por: Fahed, Akl C., et al.
Publicado: (2016)

ApoB and Non‐HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk
por: Johannesen, Camilla D. L., et al.
Publicado: (2022)

Mendelian randomization study reveals a causal relationship between adiponectin and LDL cholesterol in Africans
por: Meeks, Karlijn A. C., et al.
Publicado: (2022)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo
por: Gu, Lili, et al.
Publicado: (2017)

Regulation of plasma LDL: the apoB paradigm
por: Sniderman, Allan D., et al.
Publicado: (2009)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Hepatic S1P deficiency lowers plasma cholesterol levels in apoB-containing lipoproteins when LDLR function is compromised
por: Basu, Debapriya, et al.
Publicado: (2015)

Questioning the importance of LDL cholesterol: don’t throw the baby out with the bathwater!
por: Raal, FJ
Publicado: (2008)

A genetic variant in the LDLR promoter is responsible for part of the LDL-cholesterol variability in primary hypercholesterolemia
por: De Castro-Orós, Isabel, et al.
Publicado: (2014)

Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
por: Lee, Chan Joo, et al.
Publicado: (2017)

Uptake of (68)gallium in atherosclerotic plaques in LDLR(-/-)ApoB(100/100 )mice
por: Silvola, Johanna MU, et al.
Publicado: (2011)

Novel Presentation of Homozygous Familial Hypercholesterolemia With Homozygous Variants in Both LDLR and APOB Genes
por: Derenbecker, Robert, et al.
Publicado: (2019)

Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia
por: Lv, Xian, et al.
Publicado: (2023)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
por: Lebeau, Paul F., et al.
Publicado: (2022)

Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways
por: Yuefeng, Yu, et al.
Publicado: (2022)

Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements
por: Lai, Jiacheng, et al.
Publicado: (2021)

Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling
por: Qian, Zhengyao, et al.
Publicado: (2022)

Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA
por: Bjune, Katrine, et al.
Publicado: (2018)

Candidate Gene Analysis Reveals Strong Association of CETP Variants With High Density Lipoprotein Cholesterol and PCSK9 Variants With Low Density Lipoprotein Cholesterol in Ghanaian Adults: An AWI-Gen Sub-Study
por: Agongo, Godfred, et al.
Publicado: (2020)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Chlamydia pneumoniae Infection Exacerbates Atherosclerosis in ApoB100only/LDLR(−/−) Mouse Strain
por: Lantos, Ildikó, et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Genetic Susceptibility to Breast Cancer in Sub-Saharan African Populations
por: Hayat, Mahtaab, et al.
Publicado: (2021)

Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia
por: Gallagher, Emily J., et al.
Publicado: (2017)

Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a
por: Cui, Chuan-Jue, et al.
Publicado: (2020)

ApoB100/LDLR-/- Hypercholesterolaemic Mice as a Model for Mild Cognitive Impairment and Neuronal Damage
por: Ramírez, Carlos, et al.
Publicado: (2011)

Western Diet Decreases Hepatic Drug Metabolism in Male LDLr(−/−)ApoB(100/100) Mice
por: Koponen, Markus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sejl5l9stbbh809j24lp43e023